Non-Activated TRP Formulation With Phospholipid Dispersant
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Non-activated TRP exhibits poor solubility, leading to aggregation and precipitation, low cell permeability, and cytotoxicity, limiting its therapeutic efficacy.
Innovation Solution
A pharmaceutical formulation comprising non-activated TRP and a phospholipid dispersant, such as lecithin or Cremophor, inhibits aggregation, increases cell permeability, and reduces cytotoxicity, enhancing therapeutic efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If non-activated TRP is used as a therapeutic agent, then it exhibits high stability and robustness to temperature and acidity changes, but it shows poor solubility leading to aggregation and precipitation
Solution Approach 1:
The patent introduces a dispersant as an intermediary substance to mediate between the hydrophobic non-activated TRP and the aqueous environment. The dispersant contains both hydrophilic and hydrophobic portions that interact with TRP molecules, preventing aggregation and improving dispersibility while maintaining the stability of the polypeptide structure.
Solution Approach 2:
The patent creates a composite formulation by combining non-activated TRP with specific dispersants (such as polysorbate 80, hydroxypropyl cellulose, or polyethylene glycol). This composite system leverages the properties of both components: the high stability of TRP and the solubility-enhancing properties of the dispersant, achieving a formulation that is both stable and dispersible.
2Ease of operation
If non-activated TRP is administered at high dose to overcome low cell permeability, then cell permeability may be improved, but cytotoxicity increases
Solution Approach 1:
The patent changes the physical-chemical parameters of the TRP formulation by adjusting pH, ionic strength, and temperature to optimize cell permeability. Additionally, the use of dispersants modifies the surface properties and aggregation state of TRP, enabling effective delivery at lower concentrations that avoid cytotoxic effects while maintaining adequate cell permeability.
3Ease of manufacture
If conventional recombinant growth factors are produced using CHO or E. coli, then production is achieved, but productivity is remarkably low and production cost is expensive
Solution Approach 1:
The patent uses E. coli to produce non-activated TRP as a simplified copy or precursor form that can be later activated in vivo. This approach copies the essential functional elements of the therapeutic polypeptide while using a more productive and cost-effective production system (E. coli) compared to conventional CHO cell culture, thereby achieving high productivity and low production cost.
4Stability of the object's composition
If non-activated TRP is produced in the form of inclusion bodies, then it exhibits very high stability even at room temperature, but it requires improvement of dispersibility through inhibition of aggregation
Solution Approach 1:
The patent employs dispersants as intermediary agents that insert themselves between TRP molecules in the inclusion bodies, preventing intermolecular aggregation. These dispersants stabilize the hydrophobic surfaces of the polypeptide, allowing the inclusion bodies to be dispersed in aqueous environments without aggregating, thus converting the harmful aggregation tendency into a beneficial stable dispersed formulation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation effectively inhibits TRP aggregation, improves cell permeability, and increases stability, resulting in improved therapeutic effects.
Implementation Method 1
improve dispersibility through inhibition of aggregation and precipitation due to poor solubility of TRP
Implementation Method 2
PTD (protein transduction domain), which enables cell membrane permeation without the aid of a cell membrane receptor
Data Source
Figure 1A~1C
Figure 2A~2B
Figure 3
AI summary
The present invention relates to a pharmaceutical formulation comprising non-activated polypeptide TRP and a phospholipid dispersant. The use of the pharmaceutical formulation according to the present invention leads to the effects of suppressing the aggregation of non-activated TRP, increasing intracellular drug delivery, and decreasing cytotoxicity as well as increasing the safety of the drug and improving therapeutic efficacy.